Effects of abatacept (Orencia) on biomarkers in synovial tissue in patients with rheumatoid arthritis.

Trial Profile

Effects of abatacept (Orencia) on biomarkers in synovial tissue in patients with rheumatoid arthritis.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 10 May 2011

At a glance

  • Drugs Abatacept (Primary)
  • Indications Rheumatoid arthritis
  • Focus Biomarker; Therapeutic Use
  • Most Recent Events

    • 10 May 2011 Additional lead trial centre identified as reported by European Clinical Trials Database record.
    • 10 May 2011 New source identified and integrated (European Clinical Trials Database record EudraCT2010-021435-14).
    • 14 Dec 2010 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top